Abstract:Rosmarinic acid (RA), one of the most important polyphenol-based antioxidants, has received growing interest because of its bioactive properties, including anti-inflammatory, anticancer, and antibacterial activities. Despite the high therapeutic potential of RA, its intrinsic properties of poor water solubility and low bioavailability have limited its translation into the clinic. Here, we report on the synthesis and preparation of PEGylated RA-derived nanoparticles (RANPs) and their use as a therapeutic nanomedicine for treatment of inflammatory bowel disease (IBD) in a dextran sulfate sodium (DSS)-induced acute colitis mouse model. PEGylated RA, synthesized via a one-step process from RA and a PEG-containing amine, self-assembled in buffer to form nanoparticles (RANPs) with a diameter of 63.5 ± 4.0 nm. The resulting RANPs showed high colloidal stability in physiological medium up to 2 weeks. RANPs were capable of efficiently scavenging H2O2, thereby protecting cells from H2O2-induced damage. Furthermore, the corticosteroid drug, dexamethasone (DEX), could be loaded into RANPs and released in response to a reactive oxygen species stimulus. Intravenously administered RANPs exhibited significantly improved pharmacokinetic parameters compared with those of the parent RA and were preferentially localized to the inflamed colon. Intravenous administration of RANPs in DSS-induced colitis mice substantially mitigated colonic inflammation in a dose-dependent manner compared with the parent RA, as evidenced by significantly reduced disease activity index scores, body weight loss, and colonic inflammatory damage. In addition, RANPs suppressed expression and production of typical pro-inflammatory cytokines in the inflamed colon. Furthermore, DEX-loaded RANPs showed enhanced therapeutic efficacy in the colitis model compared with bare RANPs at the equivalent dose, indicating synergy with a conventional medication. These findings suggest that RANPs deserve further consideration as a potential therapeutic nanomedicine for the treatment of various inflammatory diseases, including IBD.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.0c01018?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.0c01018</a>.1H NMR, MALDI-TOF, UV–vis absorbance, FT-IR data of RA, mPEG2k-NH2 and PEG-RA; schematic illustration of RANP formation; zeta potential, mobility, and conductivity values, particle size and stability data of RANPs; changes in the size of RANPs induced by ROS (H2O2) stimulation; schematic illustration of formation, HPLC analysis and particle size distribution data of ; therapeutic effects of RANPs at doses of 50 and 100 mg/kg; comparison of therapeutic effects between RA and RANPs; cross-sectioned H&E images of RANP-treated colons; muscle thickness of colon sections and estimated inflammation score in DSS-induced colitis mice; representative photomicrographs of IHC sections of colons for pSTAT3, NF-kB, and neutrophils; a table for assessment of DAI; a table for assessment of histopathological colitis (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.0c01018/suppl_file/nn0c01018_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Reactive oxygen species-responsive nanocarrier ameliorates murine colitis by intervening colonic innate and adaptive immune responses

PDE9 Inhibitor PF-04447943 Attenuates DSS-Induced Colitis by Suppressing Oxidative Stress, Inflammation, and Regulating T-Cell Polarization

ROS-responsive nanoparticles for oral delivery of luteolin and targeted therapy of ulcerative colitis by regulating pathological microenvironment

Reactive Oxygen Species-Responsive Polyether Micelle Nanomaterials for Targeted Treatment of Ulcerative Colitis

Broad-Spectrum Reactive Oxygen Species Scavenging And Activated Macrophage-Targeting Microparticles Ameliorate Inflammatory Bowel Disease

ROS-responsive Nanoparticles Targeting Inflamed Colon for Synergistic Therapy of Inflammatory Bowel Disease Via Barrier Repair and Anti-Inflammation

An ROS/DAMP dual-scavenging nanomedicine for normalizing macrophage polarization and microbiome in colitis

ROS Scavenging and inflammation-directed polydopamine nanoparticles regulate gut immunity and flora therapy in inflammatory bowel disease

Integration of MyD88 inhibitor into mesoporous cerium oxide nanozymes-based targeted delivery platform for enhancing treatment of ulcerative colitis

Targeted no-releasing L-arginine-induced hesperetin self-assembled nanoparticles for ulcerative colitis intervention

Berberine-Loaded Carboxylmethyl Chitosan Nanoparticles Ameliorate DSS-Induced Colitis and Remodel Gut Microbiota in Mice

Targeted delivery of Fc-fused PD-L1 for effective management of acute and chronic colitis

Oral bomb effect nanotherapeutics alleviate ulcerative colitis through coordinated anti-inflammatory and pro-resolving strategies.

Colon-Targeting Angelica sinensis Polysaccharide Nanoparticles with Dual Responsiveness for Alleviation of Ulcerative Colitis

Macrophage‐Derived Extracellular Vesicles‐Coated Palladium Nanoformulations Modulate Inflammatory and Immune Homeostasis for Targeting Therapy of Ulcerative Colitis

Nanoparticles Derived from the Natural Antioxidant Rosmarinic Acid Ameliorate Acute Inflammatory Bowel Disease

Biomimetic MOF Nanoparticles Delivery of C-Dot Nanozyme and CRISPR/Cas9 System for Site-Specific Treatment of Ulcerative Colitis.

Colon-targeted oral nanoliposomes loaded with psoralen alleviate DSS-induced ulcerative colitis

Mo3Se4 nanoparticle with ROS scavenging and multi-enzyme activity for the treatment of DSS-induced colitis in mice

A Biomimetic Nanoplatform with Improved Inflammatory Targeting Behavior for ROS Scavenging‐Based Treatment of Ulcerative Colitis

Oral Administration of Platinum Nanoparticles with SOD/CAT Cascade Catalytic Activity to Alleviate Ulcerative Colitis